Maternal Vaccinations Act

The Maternal Vaccinations Act, S.4132, amends the Public Health Service Act to increase vaccination rates among pregnant and postpartum individuals. Specifically, it expands the focus of existing vaccination awareness campaigns to include this demographic and increases the annual appropriation for these campaigns from $15,000,000 (fiscal years 2021-2025) to $17,000,000 for fiscal years 2027 through 2031. This represents a direct, sustained increase in funding for public health initiatives promoting maternal vaccinations, leading to higher demand for relevant pharmaceutical products. The money trail for this bill flows directly into public health awareness and equity campaigns, which will drive increased procurement and administration of maternal vaccines. While the bill does not directly appropriate funds for vaccine purchases, the increased awareness and access initiatives will necessitate higher volumes of vaccine distribution. Pharmaceutical companies with established maternal vaccine portfolios are positioned to benefit. These include Pfizer ($PFE) with its RSV vaccine Abrysvo, Moderna ($MRNA) which is developing an RSV vaccine for maternal use, GSK ($GSK) also with an RSV vaccine Arexvy, Novartis ($NVS) which has a meningitis vaccine often recommended during pregnancy, and Johnson & Johnson ($JNJ) with its Tdap vaccine. The mechanism is increased demand driven by public health campaigns, leading to higher sales volumes for these companies. Historically, government-backed vaccination campaigns have consistently driven market growth for vaccine manufacturers. For example, the widespread promotion and distribution of COVID-19 vaccines in 2020-2021 led to unprecedented revenue for companies like Pfizer ($PFE) and Moderna ($MRNA). While not directly comparable in scale, the principle of government-driven demand boosting vaccine sales holds. When the Vaccines for Children program was expanded in the early 1990s, vaccine manufacturers saw sustained growth in pediatric vaccine sales. Specific price actions are difficult to isolate for such broad programs, but the long-term trend was positive for the sector. The current bill, while smaller in scope, establishes a dedicated funding stream for a specific vaccine market segment. Specific winners include Pfizer ($PFE), Moderna ($MRNA), GSK ($GSK), Novartis ($NVS), and Johnson & Johnson ($JNJ). These companies either currently produce or are developing vaccines specifically recommended for pregnant and postpartum individuals. The increased funding for awareness and equity campaigns will directly translate into higher demand for their products. There are no clear losers from this legislation, as it expands a market rather than restricting it. The bill was introduced on March 18, 2026, and referred to the Committee on Health, Education, Labor, and Pensions. Senator Kaine (D-VA) is a senior member of the Senate, which provides moderate legislative momentum. The next step is committee consideration, which could involve hearings and markups. If it passes committee, it moves to the full Senate for a vote.